We will have limited operations from 15:00 Wednesday 24 December 2025 (AEDT) until Friday 2 January 2026. Find out how to contact us during the holiday period.
Publications
Search our publications, laboratory reports, meeting statements, scheduling submissions and scheduling decisions.
Can't find what you’re looking for? You can also:
- search our Resources
- use the site search bar in the top right of this screen for more results.
Use the filters below to narrow your search.
Filter results
You can narrow down the results using the filters.
Topic
- Committees and advisory bodies (383)
- Scheduling (national classification system) (164)
- Safety monitoring and information (26)
- Advertising (25)
- COVID-19 (11)
- Manufacturing (11)
- Medicinal cannabis hub (6)
- Clinical trials (5)
- Sunscreens (5)
- Compliance and enforcement (4)
- Fees and payments (4)
- Shortages and supply disruptions (4)
- Legislation (3)
- Import and export (2)
- Breast implant hub (1)
- Cosmetics (1)
- Labelling and packaging (1)
- Metal-on-metal hip replacement implants hub (1)
- Prescription opioids hub (1)
- Unique Device Identification (UDI) hub (1)
Search
758 result(s) found, displaying 376 to 400
-
TGA laboratory testing reportsThe TGA has released a report summarising the recent laboratory testing of medicinal cannabis products
-
Corporate reportsInsights into therapeutic goods safety regulatory activity for our recalls program.
-
Corporate reportsInsights into manufacturing quality regulatory activity.
-
Corporate reportsThe TGA has published insights into recalls and GMP regulation for 2019-20.
-
Meeting statementsA meeting of the Therapeutic Goods Advertising Consultative Committee was held on 19 November 2020
-
Scheduling decisions (final)Final decisions on proposed amendments to the Poisons Standard - ACMS #31 (June 2020) and delegate only decisions relating to chemicals for agricultural and veterinary uses.
-
Scheduling decisions (final)Delegate only decisions to amend the Poisons Standard in relation to azo dyes (derivatives by diazotisation).
-
Corporate reportsResults of communication developmental research undertaken to inform consumer and health professional communication activities for the opioid regulatory reforms.
-
Scheduling decisions (interim)The closing date for public submissions on the delegate's interim decision on nicotine has been extended to Thursday 12 November 2020.
-
Meeting statementsAdvisory Committee on Medicines meeting statement
-
Meeting statementsAdvisory Committee on Medicines meeting statement
-
Meeting statementsAdvisory Committee on Medicines meeting statement
-
Meeting statementsAdvisory Committee on Medicines meeting statement
-
Meeting statementsAdvisory Committee on Medicines meeting statement
-
Meeting statementsAustralian Influenza Vaccine Committee (AIVC) recommendations
-
Corporate reportsRead our clinician information sheet on opioid analgesic tapering: summary.
-
Scheduling decisions (final)Decisions to be included in the October 2020 Poisons Standard
-
Scheduling submissionsPublic submissions on matters referred to the March 2020 scheduling meetings, and received during the interim consultation period - melatonin
-
Scheduling decisions (final)Public notice of the Delegates' final decisions to amend (or not amend) the current Poisons Standard in relation to melatonin.
-
Corporate reportsThe TGA 2019-20 Annual Performance Statistics Report has now been published.
-
Corporate reportsThis Regulation Impact Statement (RIS) is intended to assist the Australian Government in reaching a decision to address the issues relating to the safe use of sports supplements in Australia.
-
Scheduling submissionsPublic submissions on scheduling matters referred to the Joint ACMS-ACCS #25 meetings held in June 2020 - Nicotine
-
Scheduling submissionsPublic submissions made in response to the proposed amendments to the Poisons Standard referred to the ACMS #31 and Joint ACMS-ACCS #25 meetings held in June 2020
-
Corporate reportsOverview of therapeutic goods advertising complaints handling and compliance for 2019-20
-
Scheduling submissionsPublic submissions on matters referred to the March 2020 scheduling meetings, and received during the interim consultation period